M88 login Advises Nona Biosciences on its Research Collaboration and License Agreement with Candid Therapeutics

On December 16, 2024, Nona Biosciences (Suzhou) Co., Ltd. ("Nona Biosciences"), a wholly-owned subsidiary of HBM Holdings Limited (stock code: 02142.HK), announced a research collaboration M88 login license agreement to discover next-generation T-cell engagers (“TCEs”) with CM88 loginid Therapeutics, Inc. ("CM88 loginid").

Under the terms of the agreement, Nona Biosciences is eligible to receive up to USD 320 million, including an upfront payment M88 login potential milestone payments. CM88 loginid will be responsible for all further product development.

M88 login was engaged by Nona Biosciences to review and revise the agreement. With its consistent delivery of efficient and rigorous legal services and detail-oriented and professional expertise, M88 login’s team was recognized and trusted by the client.

Partnerm88 sport bettingled the M88 login team.